Corient Private Wealth LLC Has $347,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Corient Private Wealth LLC cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,827 shares of the company’s stock after selling 365 shares during the quarter. Corient Private Wealth LLC’s holdings in CRISPR Therapeutics were worth $347,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in CRISPR Therapeutics by 0.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock valued at $34,025,000 after purchasing an additional 6,635 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after buying an additional 231 shares during the period. FMR LLC grew its position in CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares in the last quarter. Captrust Financial Advisors increased its stake in CRISPR Therapeutics by 32.0% during the third quarter. Captrust Financial Advisors now owns 31,712 shares of the company’s stock valued at $1,490,000 after acquiring an additional 7,688 shares during the period. Finally, Baker BROS. Advisors LP raised its holdings in CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after acquiring an additional 743,075 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares of the company’s stock, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

CRSP has been the topic of a number of research reports. Chardan Capital lowered their price objective on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Truist Financial increased their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a research report on Wednesday, February 12th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, Citigroup decreased their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Trading Down 2.8 %

Shares of CRSP stock opened at $36.99 on Monday. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $68.39. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -8.46 and a beta of 1.77. The firm’s 50 day moving average is $43.10 and its 200-day moving average is $45.17.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.